HomeNewsTechnologyAutoWhat COVID-19? Motherson Sumi wants to nearly triple revenues to $35bn in five years

What COVID-19? Motherson Sumi wants to nearly triple revenues to $35bn in five years

A detailed roadmap for FY25, five year plan will be shared by the company in the September quarter

June 09, 2020 / 09:05 IST
Story continues below Advertisement
Vivek Chaand Sehgal, Chairman, Motherson Sumi Systems
Vivek Chaand Sehgal, Chairman, Motherson Sumi Systems

Motherson Sumi System’s desire to grow business is hitting highs, COVID-19 notwithstanding. The auto parts manufacturer wants to triple revenues to $35 billion over the next five years and develop new business segments like aerospace, defence, information technology and healthcare.

Senior executives of the Delhi-based manufacturer spoke about the company’s plans for the next five years (till FY25) in an analyst call as the previous five year plan got over with the end of FY20. The previous five year plan which started in FY16 was to achieve a three-fold increase in consolidated revenues to $18 billion but it closed well short at $12 billion.

Story continues below Advertisement

A detailed roadmap for FY25, five year plan will be shared by the company in the September quarter at an investor conference including a shift to plan 3CX10 wherein exposure to any country, component or customer should not be more than 10 percent of the total turnover by FY25. This matrix was 3CX15 for the previous five year plan.

“We are at about $12 billion (turnover). I think we are not going to extend that 5-year plan, but the next 5-year plan that we will come out will definitely give you an idea that we will try to cover up for this particular 5-year plan”, said Vivek Chaand Sehgal, Chairman, Motherson Sumi Systems (MSSL).

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show